Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

SPRO – Spero Therapeutics, Inc.

Spero Therapeutics, Inc.
SPRO
$2.37
Name : Spero Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $133,524,128.00
EPSttm : -0.79
finviz dynamic chart for SPRO
Spero Therapeutics, Inc.
$2.37
0.42%
$0.01

Float Short %

2.32

Margin Of Safety %

Put/Call OI Ratio

0.15

EPS Next Q Diff

EPS Last/This Y

1.17

EPS This/Next Y

0.77

Price

2.38

Target Price

4

Analyst Recom

3

Performance Q

-5.2

Relative Volume

0.41

Beta

1.45

Ticker: SPRO




21 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-01-13SPRO2.450.141.0011666
2026-01-14SPRO2.490.140.0011668
2026-01-15SPRO2.40.140.0011609
2026-01-16SPRO2.390.140.0011568
2026-01-20SPRO2.380.140.006736
2026-01-21SPRO2.370.140.256908
2026-01-22SPRO2.440.140.377263
2026-01-23SPRO2.450.140.007286
2026-01-26SPRO2.440.140.007286
2026-01-27SPRO2.370.130.007717
2026-01-28SPRO2.220.130.207737
2026-01-29SPRO2.260.140.007746
2026-01-30SPRO2.20.140.007762
2026-02-02SPRO2.220.13999.997912
2026-02-03SPRO2.140.140.337942
2026-02-04SPRO2.290.150.238009
2026-02-05SPRO2.30.160.018225
2026-02-06SPRO2.40.150.008379
2026-02-09SPRO2.370.150.008384
2026-02-10SPRO2.370.150.008741
2026-02-11SPRO2.380.150.008741
DateSymbolLatestP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-01-13SPRO2.45- - -0.10
2026-01-14SPRO2.50- - -0.10
2026-01-15SPRO2.40- - -0.10
2026-01-16SPRO2.40- - -0.10
2026-01-20SPRO2.39- - -0.10
2026-01-21SPRO2.37- - -0.10
2026-01-22SPRO2.44- - -0.10
2026-01-23SPRO2.44- - -0.10
2026-01-26SPRO2.44- - -0.10
2026-01-27SPRO2.37- - -0.10
2026-01-28SPRO2.22- - -0.10
2026-01-29SPRO2.26- - -0.10
2026-01-30SPRO2.20- - -0.10
2026-02-02SPRO2.22- - -0.10
2026-02-03SPRO2.14- - -0.10
2026-02-04SPRO2.29- - -0.10
2026-02-05SPRO2.31- - -0.10
2026-02-06SPRO2.40- - -0.10
2026-02-09SPRO2.37- - -0.10
2026-02-10SPRO2.37- - -0.10
2026-02-11SPRO2.38- - -0.10
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-01-13SPRO-0.310.262.31
2026-01-14SPRO-0.310.262.31
2026-01-15SPRO-0.310.262.31
2026-01-16SPRO-0.310.262.31
2026-01-20SPRO-0.310.142.31
2026-01-21SPRO-0.310.142.31
2026-01-22SPRO-0.310.142.31
2026-01-23SPRO-0.310.142.31
2026-01-26SPRO-0.310.132.31
2026-01-27SPRO-0.310.132.31
2026-01-28SPRO-0.310.132.54
2026-01-29SPRO-0.310.132.54
2026-01-30SPRO-0.310.132.54
2026-02-02SPRO-0.310.132.54
2026-02-03SPRO-0.310.132.54
2026-02-04SPRO-0.310.132.54
2026-02-05SPRO-0.730.132.54
2026-02-06SPRO-0.730.132.54
2026-02-10SPRO-1.380.382.56
2026-02-11SPRO-1.380.382.32
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.13

Avg. EPS Est. Current Quarter

-0.2

Avg. EPS Est. Next Quarter

Insider Transactions

-1.38

Institutional Transactions

0.38

Beta

1.45

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

14

Growth Score

37

Sentiment Score

94

Actual DrawDown %

88.9

Max Drawdown 5-Year %

-97.4

Target Price

4

P/E

Forward P/E

3.54

PEG

P/S

4.55

P/B

5.04

P/Free Cash Flow

EPS

-0.79

Average EPS Est. Cur. Y​

-0.1

EPS Next Y. (Est.)

0.67

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-149.52

Relative Volume

0.41

Return on Equity vs Sector %

-193.3

Return on Equity vs Industry %

-177

EPS 1 7Days Diff

EPS 1 30Days Diff

0.29

EBIT Estimation

Spero Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 32
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candidate for first-line treatment of nontuberculous mycobacterial (NTM) pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to the oral prodrug SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
stock quote shares SPRO – Spero Therapeutics, Inc. Stock Price stock today
news today SPRO – Spero Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch SPRO – Spero Therapeutics, Inc. yahoo finance google finance
stock history SPRO – Spero Therapeutics, Inc. invest stock market
stock prices SPRO premarket after hours
ticker SPRO fair value insiders trading